- Redwood City, CA-based Dermira (NASDAQ:DERM) is set for its IPO of 5.35M shares at $14 - 16. As the name implies, the clinical stage biopharmaceutical firm focuses on the dermatology space. It has three late-stage product candidates:
- Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor (TNF inhibitor) for the treatment of moderate-to-severe plaque psoriasis. Cimzia is owned and marketed by Belgian biopharma firm UCB for other inflammatory diseases. Dermira signed a collaboration deal with UCB to develop Cimzia for psoriasis. It intends to commence a Phase 3 trial in 1H 2015.
- DRM04, a topical small molecule anticholinergic for the treatment of hyperhidrosis. It blocks the action of acetylcholine and therefore blocks the activation of the sweat glands. Data from a Phase 2b trial should be available in 1H 2015. If successful, a Phase 3 trial will commence in 2H 2015.
- DRM01, a topical small molecule sebum inhibitor for the treatment of acne. A Phase 2b clinical program, which may include more than one trial, should commence in 1H 2015.
- S-1
- ETFs: IBB, BIB, BIS